Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance.
According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment.
"At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health."
Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles.
"Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication."
Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity.
For more information or to access the GoodRx Contrave savings card, visit: https://www.goodrx.com/contrave. *Program benefit maximums and eligibility restrictions may apply.
About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit www.curraxpharma.com.
About CONTRAVE:
CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to www.CONTRAVE.com.
Media Contactcurrax@ampublicrelations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/currax-expands-access-to-fda-approved-obesity-treatment-with-brand-name-contrave-with-new-cash-price-available-via-goodrx-302505664.html
SOURCE Currax Pharmaceuticals LLC
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
ELFI study shows college meal plans to be a significant portion of college costs
Popular cost-cutting advice to skip meal plans may not be feasible for most students KNOXVILLE, Tenn., July 29, 2025 /PRNewswire/ -- A recent study by student loan lender ELFI surveyed current meal plan pricing at 150 colleges and universities nationwide, concluding that 98% of surveyed institutions require freshmen to purchase meal plans. This makes a common cost-cutting strategy – skipping meal plans in favor of home-cooked meals – impractical for many students. Meal plans can present a significant expense among college-related costs. ELFI found that current plans average $5,600 per academic year, totaling anywhere from $12,000 to $44,000 over four years. Private school meal plans cost 22% more than public school plans on average. The study also found that college meal plans are considerably more expensive than the standard cost of meals, based on the average range of nutritious, home-prepared food plans measured by the U.S. Department of Agriculture (USDA) for adults ages 19 to 50. On average, student meal plans were 39-49% more expensive than USDA food plans, depending on the sex of the student. Considering this cost amid recent inflation trends, many financial experts recommend that students prepare their own meals to save money. However, meal plans are typically required for students living on campus, especially for freshmen. As a result, students and families may be budgeting based on outdated or impractical advice and could be blindsided by the true cost of attendance. "Borrowers come to us with concerns about how to maximize long-term savings while financing their college education," said Ivan Marcinko, ELFI senior vice president and director of operations. "We hope that this study will help families understand that some college costs cannot be mitigated and encourage them to explore financing pathways that accommodate the high cost of college, including meal plans." College costs are top of mind for many student loan borrowers considering the recently signed "One Bill Big Beautiful Bill" Act, which included various reforms aimed at financial aid and student loan repayment. As grant limits, loan caps and other higher education lending reforms go into effect, students and families may need to make critical decisions about meeting the cost of college with a combination of federal aid, institutional assistance and private lending. For some students, institutional meal plan assistance programs, waivers or exceptions may be available. ELFI recommends that students contact their college or university to learn more about their options. ELFI is a division of Tennessee-based SouthEast Bank and offers nationwide student loans. Since launching in 2015, ELFI has offered a range of student loan and refinancing products and services backed by an award-winning team of student loan advisors who work one-to-one with borrowers through the application process from start to finish. About Education Loan Finance (ELFI) ELFI is a nationwide student loan provider and refinance program offered by Tennessee-based SouthEast Bank. Since its launch in 2015, ELFI has assisted borrowers with student loan refinancing as well as with undergraduate, graduate and parent private student loans. ELFI makes financing your future simple by offering easy payment options, affordable rates, and flexible terms in an application process that is transparent and secure. Learn more at Media Contact Mary Seward SouthEast Bank Marketing Manager mseward@ 865-352-1262 View original content to download multimedia: SOURCE ELFI
Yahoo
9 minutes ago
- Yahoo
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
Novo Nordisk's (NVO) downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ability to maintain a market lead in the obesity drug space. The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen told reporters Tuesday that the compounding, or copycat, market in the US is to blame. That is one of two key issues that appear to have taken the company by surprise. First was the shortage of both its GLP-1 drugs after they unexpectedly zoomed to popularity, creating a new weight-loss drug market. Jørgensen said that the prevalence of compounded products, which are now restricted after the FDA declared an end to the shortage, is to blame. "Despite the fact that it is now illegal ... it's still happening. And that's one of the assumptions in the prior guidance, that that would be reduced significantly. And we see, actually, that is actually the same volume as we saw earlier in the year, around a million patients using a compounded product," Jørgensen said. The compounded products include those from Novo's ex-partner, Hims & Hers (HIMS), which continues to sell the products based on a loophole in FDA rules that allows it to sell "personalized" products for patients who might have negative reactions or side effects to branded drugs — such as common GLP-1 side effects like nausea or dizziness. Novo recently ended its direct-to-consumer sales deal with Hims after the telehealth firm declined to stop selling compounded semaglutide vials. The result has been a loss in the company's first-to-market position, with competitor Eli Lilly (LLY) taking a harder stance, most recently lobbying Congress to help enforce the FDA rules and rid the market of compounding. Jørgensen said Tuesday, "Ultimately, compounding will disappear. But it will take some time before it's completely out of the market and we have a fair chance of regaining our fair share (of the market)." Incoming CEO Mike Doustdar, who has served as Novo's executive vice president of international operations, said the decline of the company's stock, and therefore shareholder value, is disappointing. "I don't like it as an employee ... as a CEO-elect, and I certainly don't like it as a shareholder myself. But setbacks don't define companies, our response does," Doustdar said, adding that the guidance cut reinforces his mandate to put the company back onto a growth path. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
The Hill
10 minutes ago
- The Hill
‘Tariff rebates' proposed: How would they work?
(NEXSTAR) — If you've been waiting and hoping for another stimulus check since receiving your last COVID relief payment in 2021, you may be in luck. Sen. Josh Hawley (R-Mo.) has introduced legislation that would send out 'tariff rebates' meant to 'allow hard-working Americans to benefit from the wealth that Trump's tariffs are returning to this country.' As The Hill reports, the rebates would be modeled after the payments sent out after Congress authorized the 2020 CARES Act. In that case, adults received direct payments of $1,200 and $500 for their dependent children. Hawley introduces bill to provide $600 tariff rebates to adults and children Unlike those payments, these rebates would serve to offset the higher prices consumers have faced amid tariffs. According to Hawley, the U.S. has recorded $30 billion in tariff revenue as of June. He cited additional projections that say the revenue could exceed $150 billion this year alone. Under Hawley's bill, however, the individual payments would be much smaller. How much would the tariff rebates be? Each adult would receive 'at least $600,' as would each dependent child. The total rebate for a DINK (dual income, no kids) household, for example, would be at least $1,200, while a family of four could receive $2,400. Payments could increase 'if tariff revenue exceeds current projections for 2025,' according to a press release from Hawley's office describing the proposed legislation. Who will — and won't — have a three-payday August Payments would also decrease based on household income. The bill's text says rebates would be reduced based on a taxpayer's filing status and their adjusted gross income. That income threshold is $150,000 for those filing a joint return; $112,500 for those filing as a head of household; and $75,000 for a single taxpayer. Who would be eligible for a payment? Hawley's bill does not explicitly outline who would be eligible, but rather who is ineligible. That includes: 'any nonresident alien individual'; those who can be claimed on another taxpayer's taxes; and estates or trusts. As we saw with the COVID stimulus checks, your most recent taxes would likely be used to determine your eligibility and the size of your payment. When could tariff rebates be sent out? It's too early to say, as Hawley's bill would still need to make it through Congress. President Donald Trump has expressed support for the idea, telling reporters last week that the U.S. has 'so much money coming in' because of the tariffs that 'we're thinking about a little rebate.' 'A little rebate for people of a certain income level might be very nice,' he said, while noting that 'the big thing we want to do is pay down the debt.' As of Tuesday, the federal deficit sits at roughly $36.7 trillion. If you would like to help pay it down, you can now use Venmo to contribute to the 'Gifts to Reduce the Public Debt' program.
